statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts

Latest Ratings for PCRX
 DateFirmActionFromTo Feb 2022WedbushMaintainsOutperform Feb 2022HC Wainwright & Co.MaintainsBuy Jan 2022BarclaysMaintainsOverweight
 View More Analyst Ratings for PCRX...

Commit To Purchase Pacira BioSciences At $15, Earn 12.5% Annualized Using Options

Investors considering a purchase of Pacira BioSciences Inc (PCRX) shares, but cautious about paying the going market price of 29.22/share, might benefit from considering selling puts among the...

Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

TAMPA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 23rd Annual Needham Virtual...

Pacira BioSciences (PCRX, $29.29) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 21, 2024

This is a Bearish indicator signaling PCRX's price could decline from here. Traders may explore shorting the stock or put options...

Pacira BioSciences (PCRX, $30.02) entered Downtrend as Momentum indicator drops below 0 level on Mar 20, 2024

This indicator may be signaling that PCRX's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Pacira BioSciences (PCRX, $30.02) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 20, 2024

This is a Bullish indicator signaling PCRX's price could rise from here. Traders may explore going long the stock or buying call options...

Pacira BioSciences (PCRX, $29.3) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 18, 2024

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

-- PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis -- -- Designation supported by encouraging preliminary data from 72-patient Phase 1 study...

Pacira BioSciences (PCRX, $31.04) price exceeded its 50-day Moving Average on March 11, 2024

This price move could indicate a change in the trend, and may be a sell signal for investors...

Pacira BioSciences (PCRX, $29.44) entered Downtrend as Momentum indicator drops below 0 level on Mar 05, 2024

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Volume	973,328.00
52-Wk High	$40.16
52-Wk Low	$19.34

PCRX Pacira BioSciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals